MedTrace Logo

Study on the Application of Hyperspectral Imaging Technique in the Treatment of IMN by TAC

NCT05797038 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2023-04-04

No results posted yet for this study

Summary

We propose hyperspectral imaging analysis as a method to identify the efficacy of hormone-tacrolimus therapy for PMN, and to classify sensitive and insensitive patients treated with hormone-tacrolimus regimen. A variety of machine learning models were used to prove that hyperspectral imaging technology could assist patients in selecting the optimal treatment plan, and further explore the predictive indicators of PMN treatment effect.

Conditions

  • Idiopathic Membranous Nephropathy
  • Tacrolimus
  • Hyperspectral Imaging

Interventions

DRUG

Tacrolimus for the treatment of IMN

Remission after tacrolimus treatment of IMN

Sponsors & Collaborators

  • Qianfoshan Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-25
Primary Completion
2023-07-20
Completion
2023-12-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05797038 on ClinicalTrials.gov